吉利德概念普漲 博騰股份、永太科技連續第五日漲停
格隆匯2月7日丨吉利德概念股今日繼續上漲,其中,博騰股份(300363.SZ)連續第五日漲停,報25.39元;永太科技(002326.SZ)連續第五日漲停,報18.62元;九洲藥業(603456.SH)逼近漲停;藥明康德H股漲超1%,A股微跌。吉利德的抗病毒藥瑞德西韋臨牀試驗已在武漢金銀潭醫院啟動,一位上海某三甲醫院從事造血幹細胞的研究人員稱,兩週之內瑞德西韋的臨牀試驗結果有望公開。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.